Forte Biosciences, Inc.

The momentum for this stock is not very good. Forte Biosciences, Inc. is not a good value stock. Forte Biosciences, Inc. is not very popular among insiders. Forte Biosciences, Inc. is a mediocre stock to choose.

News

Stock Traders Purchase High Volume of Call Options on Forte Biosciences (NASDAQ:FBRX)

Zolmax Forte Biosciences, Inc. (NASDAQ:FBRX - Get Free Report) was the target of some unusual options trading activity on Wednesday. Traders bought 30,205 call options on the stock. This is an increase of...\n more…

Forte Biosciences trading halted, news pending

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

FY2024 EPS Estimates for Forte Biosciences, Inc. Cut by Chardan Capital (NASDAQ:FBRX)

Ticker Report Forte Biosciences, Inc. (NASDAQ:FBRX - Free Report) - Stock analysts at Chardan Capital cut their FY2024 earnings per share estimates for shares of Forte Biosciences in a research report issued to...\n more…

Forte Biosciences Sees Unusually Large Options Volume (NASDAQ:FBRX)

Ticker Report Forte Biosciences, Inc. (NASDAQ:FBRX - Get Free Report) was the recipient of unusually large options trading on Wednesday. Stock traders purchased 30,205 call options on the company. This represents...\n more…

Chardan Capital Reaffirms Buy Rating for Forte Biosciences (NASDAQ:FBRX)

Ticker Report Forte Biosciences (NASDAQ:FBRX - Get Free Report)s stock had its "buy" rating reaffirmed by stock analysts at Chardan Capital in a research report issued to clients and investors on Monday...\n more…

Forte Biosciences (NASDAQ:FBRX) Posts Earnings Results, Misses Estimates By $0.11 EPS

Zolmax Forte Biosciences (NASDAQ:FBRX - Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($0.27) earnings per share for the quarter, missing analysts' consensus...\n more…